

In the name of God

Curriculum Vitae

First name: **Monireh**

Last name: **Mohsenzadegan**

Tel: **+989124248518**

E-mail: **monirehmohsenzadegan@gmail.com**

Mohsenzadegan.m@iums.ac.ir

Education

2008-2014	Ph.D., Immunology, Iran University of Medical Sciences, Tehran, Iran
2006-2008	MS.c., Immunology, Tehran University of Medical Sciences, Tehran, Iran
2001-2004	B.Sc, laboratory sciences, Tehran University of Medical Sciences, Tehran, Iran

Category of Research

Tumor Immunology

Academic degree

Assistant Professor

Affiliation

Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

Course Teaching

Medical students of Iran university of medical sciences and AJA university of medical sciences

Teaching titles:

Vaccination
Tumor immunology
Autoimmune diseases
Tolerance
Widal test
ASO test
Wright test
ELISA
RF/CRP/beta HCG/ RPR tests

Ph.D students of Iran university of medical sciences

Teaching titles:

Immunohistochemistry
Tissue Microarray
Flow cytometry

M.Sc students of Iran university of medical sciences

Teaching titles:

Immunohistochemistry
Flow cytometry
ELISA
Tests of phagocytosis

Fellowship of laboratory sciences of Iran university of medical sciences

Teaching titles:

Immunohistochemistry and tissue microarray
Tumor markers
Diagnostic Testing and Interpretation of Tests for Autoimmunity

B.Sc students of Iran university of medical sciences

Teaching titles:

Innate immunity
B cell development
T cell development
Tolerance
Complement system
Autoimmune diseases
Tumor immunology
Widal test
ASO test
ELISA
RF/CRP/beta HCG tests
NBT test

Flow cytometry

Published Articles

- 1)Esfidani M , Ayatollahi Mousavi SA , Yazdanparast A , Shafiee M and **Mohsenzadegan M**. Determination of Changes in the Expression of MIR-212 and EGFR Genes in Clinical Samples from Areas Infected with *Trichophyton rubrum* Compared with Non-Infected Areas. *Jundishapur J Microbiol.* **2018**; 11(11):e62885
- 2)Shahrabi Farahani M, **Mohsenzadegan M**, Taeb J, Farajollahi MM. In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticles. *Med J Islam Repub Iran.* **2019**(12 March);33.16.
- 3)**Mohsenzadegan M***, Seif F, Farajollahi MM, Khoshmirsafa M. Anti-Oxidants as Chemopreventive Agents in Prostate Cancer: A Gap Between Preclinical and Clinical Studies. *Recent Pat Anticancer Drug Discov.* **2018**;13(2):224-239.
- 4)Gholipour-Kanani A, **Mohsenzadegan M**, Fayyazi M, Bahrami H, Samadikuchaksaraei A. Poly (ϵ -caprolactone)-chitosan-poly (vinyl alcohol) nanofibrous scaffolds for skin excisional and burn wounds in a canine model. *IET Nanobiotechnol.* **2018** Aug;12(5):619-625.
- 5)**Mohsenzadegan M**, Saebi F, Yazdani M, Abolhasani M, Saemi N, Jahanbani F, Farajollahi MM. Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients. *Biomark Med.* **2018** Oct;12(10):1125-1138.
- 6)Jamalpoor Z, Asgari A, Lashkari MH, Mirshafiey A, **Mohsenzadegan M**. Modulation of Macrophage Polarization for Bone Tissue Engineering Applications. *Iran J Allergy Asthma Immunol.* **2018** Oct 7;17(5):398-408.
- 7)Seif F, Sharifi L, Khoshmirsafa M, Mojibi Y, **Mohsenzadegan M***. A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer. *Curr Drug Targets.* **2019**;20(7):789-798.
- 8) Kalantari E, Abolhasani M, Roudi R, Farajollahi MM, Farhad S, Madjd Z, Askarian-Amiri S, **Mohsenzadegan M***. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. *Int J Exp Pathol.* **2019** Apr;100(2):123-132.
- 9) **Mohsenzadegan M**, Peng RW, Roudi R. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. *J Cell Physiol.* **2019** Jun 21.
- 10)Roudi R., Mohammadi SR, Roudbary M, **Mohsenzadegan M***. Lung cancer and β -glucans: review of potential therapeutic applications; *Invest New Drugs* ;**2017**, doi: 10.1007/s10637-017-0449-9 (In press).
- 11) Sharifi L, Tavakolinia N, Kiaee F, Rezaie N, **Mohsenzadegan M**, Shariat M, Yazdani R, Mirshafiey A, Aghamohammadi A, Azizi G. A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency. *Endocr Metab Immune Disord Drug Targets*; **2017** Jun 13 (In press).

12) Seif F, Khoshmirsafa M, Aazami H, **Mohsenzadegan M**, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. *Cell Commun Signal*; **2017** Jun 21;15(1):23.

13) Sharifi L, **Mohsenzadegan M**, Aghamohammadi A, Rezaei N, Tofighi Zavareh F, Bokaie S, Moshiri M, Azizi G, Mirshafiey A, Aghazadeh Z. Immunomodulatory effect of G2013 (alpha-L-Guluronic acid) on the TLR2 and TLR4 in human mononuclear cells. *Curr Drug Discov Technol*. **2017** Jun 4 (In press).

14) Sharifi L, Aghamohammadi A, **Mohsenzadegan M**, Rezaei N, Towfighi Zavareh F, Moshiri M, Bokaie S,

Barati A, Sayedi SJ, Azizi GH, Mirshafiey A. Immunomodulation of TLR2 and TLR4 by G2013 (alpha-L-Guluronic acid) in CVID Patients. *International Journal of Pediatrics* July. **2017**, Page 5327-5337.

15) **Mohsenzadegan M**, Sharifi R, Taromi N, Farajollahi MM. Evaluation of Direct Effect of Testosterone on NGEP and LMO1 Expression in LNCaP Prostate Cancer Cells; *Current Biomarkers*; **2017**, DOI: 10.2174/2468422807666170222091437.

16) **Mohsenzadegan M**, Shekarabi M, Madjd Z, Asgari M, Abolhasani M, Tajik N, Farajollahi MM. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. *Biomarkers in Medicine*. **2015**; 9(4):391-401.

17) **Mohsenzadegan M**, Tajik N, Madjd Z, Shekarabi M, Farajollahi MM. Study of NGEP expression in androgen sensitive prostate cancer cells; a potential target for immunotherapy. *Medical Journal of Islamic Republic of Iran*. **2015**;29:159.

18) **Mohsenzadegan M**, Mohammad Reza Fayazi, Mohsen Abdolmaleki, Masoomeh Bakhshayesh, Farhad Seif, Kazem Mousavizadeh. Direct immunomodulatory influence of IFN- β on human astrocytoma cells. *Immunopharmacol Immunotoxicol*. **2015**;37(2):214-9.

19) **Mohsenzadegan M**, Fattahi Fa, Fattahi F, Mirshafiey A, Fazlollahi MR, Naderi F, Movahedi M, Pourpak Z. Altered Pattern of Naive and Memory B cells and B1 Cells in Patients with Chronic Granulomatous Disease. *Iran J Allergy Asthma Immunol*. June **2014**; 13(3):157-165.

20) **Mohsenzadegan M**, Madjd Z, Asgari M, Abolhasani M, Shekarabi M, Taeb J, Shariftabrizi A. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. *Cancer Immunol Immunother*. **2013** Oct;62(10):1609-18.

21) **Mohsenzadegan M**, Mirshafiey A. The immunopathogenic role of reactive oxygen species in Alzheimer disease. *Iran J Allergy Asthma Immunol*. **2012** Sep;11(3):203-16.

22) Naderi beni F, Fattahi F, Mirshafiey A, Ansari M, **Mohsenzadegan M**, Movahedi M, Pourpak Z, Moin M. Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. *Int Immunopharmacol*. **2012** Apr;12(4):689-93.

23) Mirshafiey A , **Mohsenzadegan M**. Opioids and opioid receptor in multiple sclerosis. The journal of Chinese clinical medicine. March **2010**; 5:3.

24) Mirshafiey A, **Mohsenzadegan M**. Neuropharmacology.TGF-beta as a promising option in the treatment of multiple sclerosis. **2009** May-Jun;56(6-7):929-36.

25) Mirshafiey A,**Mohsenzadegan M**. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol. **2009**;31(1):13-29.

26) Mirshafiey A , **Mohsenzadegan M**. Immunotoxicological effects of reactive oxygen species in multiple sclerosis. J of Chinese clinical medicine. July **2008**; 3:7.

27) Mirshafiey A, **Mohsenzadegan M**. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. Iran J Allergy Asthma Immunol. **2008** Dec;7(4):195-202.

28) Namaki S, **Mohsenzadegan M**, Mirshafiey A. Superoxide dismutase: A light horizon in treatment of multiple sclerosis. Journal of Chinese Clinical Medicine;**2009**, Vol. 4 Issue 10, p585.

29) Khoshmirsafa M, Seif F, **Mohsenzadegan M**, Najafi M, Mokhtarian K, Shekarabi M. Circulating microRNAs, valuable biomarkers in biological fluids. RJMS **2017**, 24(160): 22-36.

30) Gholipour-Kanania A, Samadikuchaksaraei A, **Mohsenzadegan M**, Fayyazi MR. Nanofibrous scaffolds from chitosan and poly(caprolactone) for excision wound healing application in canine model. Material today: proceeding. Volume 5, Issue 7, Part 3, **2018**, Pages 15629-15634.

Congress articles as oral or poster presentation

1)**Mohsenzadegan M***, Madjd Z, Shekarabi M, Farajollahi MM. Characterization of peptides derived from extracellular portions of NGEP-L by using Ab production and their investigations on tissue of prostate cancer in **11 th International Congress of Immunology & Allergy, 26-29 April ,Iran.**

2)**Mohsenzadegan M***, Fattahi F, Naderi F, Pourpak Z. Immunophenotyping in subgroup of B lymphocyte in CGD patients in **11 th International Congress of Immunology & Allergy,26-29 April, 2012, Iran.**

3)**Mohsenzadegan M***, Shekarabi M, Farajollahi MM, Madjd Z. Preparation of polyclonal antibodies against extracellular NGEP protein; as a potential biomarker in prostate cancer immunotherapy. **12 th International Congress of Immunology & Allergy, 29 April-2May,2014, Iran.**

4) **Mohsenzadegan M***, Madjd Z, Asgari M, Abolhasani M, Shekarabi M. Assessment of new gene expressed in prostate (NGEP) in human prostate tissues using tissue microarray analysis. **12 th International Congress of Immunology & Allergy, 29 April-2May,2014, Iran.**

5) **Mohsenzadegan M***, Tajik N, Farajollahi MM, Shekarabi M. Investigation of NGEP expression levels in two standard prostate cancer cell lines. **12 th International Congress of Immunology & Allergy, 29 April-2May,2014, Iran.**

6) **Mohsenzadegan M***, Sharifi R, Farajollahi MM. Direct effect of testosterone on NGEP and LMOLMO1 expression in prostate cancer cells. **9 th International Congress of Laboratory & Clinic- 21-24 Feb, 2017, Iran.**

7) Esfidani M, Ayatollah Mousavi A, Yazdanparast A, Shafiee M, **Mohsenzadegan M**. Determination of changes in the expression of miR-212 and EGFR genes in clinical specimens of dermatophyte infections with *Trichophyton rubrum* in affected areas in comparison with adjacent healthy spots. **20 th Congress of the International Society for Human and Animal Mycology- on 30 June- 4 July 2018. Amsterdam, Netherlands.**